Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04783415
Title Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors City of Hope Medical Center
Indications

mantle cell lymphoma

Therapies

Acalabrutinib + Ublituximab + Umbralisib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST